Volitionrx Executive Compensation
VolitionRx CEO Cameron Reynolds agreed to a further temporary reduction in his annual base salary from $355,456 to $236,970.50 as part of the company's cost-reduction measures. This follows a previous 25% reduction effective February 2026, bringing his total salary down from a contractual base of $473,941. The reduction will remain in effect until the Compensation Committee determines the company's financial stability is secured, potentially following a significant licensing or commercial agreement.
- Term
- temporary